Cargando…

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

BACKGROUND: The adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data. METHODS—PRECLINICAL STUDY: The impact of tumor size on ADC tumor delivery and treatment response was evaluated in an EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gan, Hui K, Parakh, Sagun, Lassman, Andrew B, Seow, Aidan, Lau, Eddie, Lee, Sze Ting, Ameratunga, Malaka, Perchyonok, Yuliya, Cao, Diana, Burvenich, Ingrid J G, O’Keefe, Graeme J, Rigopoulos, Angela, Gomez, Erica, Maag, David, Scott, Andrew M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446913/ https://www.ncbi.nlm.nih.gov/pubmed/34549181 http://dx.doi.org/10.1093/noajnl/vdab102

Ejemplares similares

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
por: Lassman, Andrew B, et al.
Publicado: (2019)

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
por: van den Bent, Martin, et al.
Publicado: (2017)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022)

Molecular imaging of T cell co-regulator factor B7-H3 with (89)Zr-DS-5573a
por: Burvenich, Ingrid Julienne Georgette, et al.
Publicado: (2018)

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin
por: Vize, Colin J., et al.
Publicado: (2023)

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
por: Chia, Puey-Ling, et al.
Publicado: (2020)

Radiolabeled Antibodies for Cancer Imaging and Therapy
por: Parakh, Sagun, et al.
Publicado: (2022)

l-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies
por: Lee, Fook T., et al.
Publicado: (2016)

Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial
por: Narita, Yoshitaka, et al.
Publicado: (2021)

Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers
por: Burvenich, Ingrid J. G., et al.
Publicado: (2016)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
por: Greening, David W., et al.
Publicado: (2015)

Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways
por: Greening, David W., et al.
Publicado: (2016)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach
por: Coleman, Niamh, et al.
Publicado: (2018)

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
por: Goss, Glenwood D., et al.
Publicado: (2018)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

In Vitro and In Vivo Evaluation of (89)Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy
por: Burvenich, Ingrid J.G., et al.
Publicado: (2016)

Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
por: Randon, Giovanni, et al.
Publicado: (2023)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021)

Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Dramatic clinical response in the treatment of small cell glioblastoma multiforme
por: Zaman, Farzana Yasmin, et al.
Publicado: (2022)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer
por: Wang, X, et al.
Publicado: (2014)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
por: Carrasco, J, et al.
Publicado: (2015)

SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling
por: Barzegar, Mansoureh, et al.
Publicado: (2017)

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
por: Yoshida, Ryohei, et al.
Publicado: (2022)

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer
por: Gibault, L, et al.
Publicado: (2005)

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
por: Jimeno, A, et al.
Publicado: (2007)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_m0o43em8fam352bp0df7qanngh